NYSE:CANF 18 November 2025

Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update

Can-Fite BioPharma Ltd. rallied in premarket trading Friday after reporting a Japanese patent allowance for Namodenoson targeting obesity. The move was strong but volume stood out as cleaner signal, with a late MarketWatch quote putting the ADR at $3.44 by 8:54 a.m. EDT, up 50 cents or 16.99%. Volume print was 21.73 million shares before the open. NYSE American’s regular trading starts at 9:30 a.m. ET, and June 26 is not shown as a 2026 U.S. equity-market holiday.

26 June 2026

NYSE:CANF·Stock Market

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Shares of Can-Fite BioPharma Ltd. jumped on Tuesday after the company reported a striking 9‑year overall survival with a complete response in an advanced liver cancer patient treated with its investigational drug Namodenoson, and confirmed that a pivotal Phase III trial in hepatocellular carcinoma is now enrolling patients in multiple regions. GlobeNewswire+1

18 November 2025